TICKERNERD
Menu
TFXTFXHealthcare · Medical Instruments & Supplies

TFX Stock Forecast: Teleflex, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$125
+0.90% on the day

The 13 Wall Street analysts covering Teleflex, Inc. hold a median 12-month price target of $155 — +23.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 3 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$5.3B
Ticker Nerd rank
80 / 100
Median analyst target
$155
Analysts covering
13
Revenue$570.3M−27.0% y/y
Operating income$73.1M
Net income$99.7M
Free cash flow$80.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.7%
1M
−9.5%
YTD
+3.4%
1Y
−3.3%
From 52W high
−11.8%
From 52W low
+25.8%
$100
$142
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TFX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Teleflex, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Value
93
Revisions
89
Volatility
78
Momentum
63
Issuance
50
Quality
45
Growth
28
Size
22

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TFX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TFX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26TFXHigh $170Median $155Low $138

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
6 Buy7 Hold0 Sell
Low $138Median $155High $170

The green dot is the last close — the median target sits +23.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
28 Sept 2026B of A SecuritiesUpgradeBuy$145 → $158
25 Aug 2026NeedhamMaintainsBuy$159 → $170
25 Aug 2026NeedhamMaintainsBuy—
11 Aug 2026UBSMaintainsNeutral$145 → $158
11 Aug 2026UBSMaintainsNeutral—
10 Aug 2026Truist SecuritiesMaintainsHold—
10 Aug 2026Truist SecuritiesMaintainsHold$143 → $150
7 Aug 2026Piper SandlerReiteratesOverweight—
7 Aug 2026Piper SandlerReiteratesOverweight$160 → $169
31 July 2026NeedhamMaintainsBuy$147 → $159
31 July 2026NeedhamMaintainsBuy—
28 July 2026UBSInitiatesNeutral$145
28 July 2026UBSInitiatesNeutral—
15 July 2026MizuhoMaintainsNeutral$140 → $145
15 July 2026MizuhoMaintainsNeutral—
9 July 2026BMO CapitalInitiatesOutperform$159
9 July 2026BMO CapitalInitiatesOutperform—
8 June 2026Piper SandlerUpgradeOverweight—
11 May 2026Truist SecuritiesReiteratesHold—
8 May 2026RBC CapitalUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TFX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TFX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, Teleflex, Inc. returned −3.3% against +16.2% for the S&P 500, dividends included.

TFX vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26TFXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TFX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.3%
Analysts raising
10
Analysts cutting
0
Fundamentals

Teleflex, Inc. (TFX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2735.6×

Cheaper than 1% of US stocks

Price / sales
2.3×

Cheaper than 48% of US stocks

Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
19.5×

Cheaper than 16% of US stocks

Growth & margins
Revenue growth (YoY)
28.9%

Higher than 77% of US stocks

Earnings growth (YoY)
−18.7%

Higher than 21% of US stocks

Gross margin
58.2%

Higher than 71% of US stocks

Operating margin
10.1%

Higher than 64% of US stocks

Net margin
−45.8%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−0.7%

Higher than 43% of US stocks

Return on assets
1.7%

Higher than 57% of US stocks

Dividend yield
1.1%

Higher than 53% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Teleflex, Inc. (TFX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Teleflex, Inc. has a market value of $5.3B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $1.6B. The latest quarter grew 28.9% year on year.

  • Net income over the same four quarters: −$1.0B, a −63.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−23.29.

  • Free cash flow in the twelve months to 30 June 2026: $327.1M, after $76.1M of capital spending.

  • Teleflex, Inc. spent $250.0M on share buybacks and $59.9M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 42.4M.

  • Trailing P/E: 2735.6×; forward P/E: 11.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.09%, paying out 104% of earnings.

  • Teleflex, Inc. employs 15,500 people — $105K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

TFX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
TFXTeleflex, Inc.$5.3B
80
STVNStevanato Group SpA$5.5B
68
MMEDMiniMed Group, Inc.$5.5B
2
MMSIMerit Medical Systems, Inc.$5.1B
92
BLCOBausch + Lomb Corp.$6.1B
88
ICUIICU Medical, Inc.$3.9B
97
ATRAptarGroup, Inc.$7.9B
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Teleflex, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TFX news & analysis

Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Business Wire · 29 Sept 2026positive

Teleflex announced the publication of a peer-reviewed study in the American Journal of Infection Control showing that central venous catheters protected with Arrowg+ard Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections compared with plain, non-impregnated catheters over a 30-day period.

Why it matters — This peer-reviewed clinical evidence supporting the effectiveness of Teleflex's Arrowg+ard Technology could strengthen the competitive positioning of one of its key medical device products.

Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?

Zacks Investment Research · 29 Sept 2026positive

Teleflex shares rose 4.4% in the last trading session on above-average volume. The recent trend in earnings estimate revisions suggests potential for further near-term price increases.

Why it matters — A TFX watcher would care because the higher trading volume and improving earnings estimate revisions may signal continued upward momentum for the stock.

Here's Why Teleflex (TFX) is a Strong Value Stock

Zacks Investment Research · 16 Sept 2026positive

Zacks Investment Research highlights Teleflex (TFX) as a strong value stock using its Style Scores feature, which helps identify stocks across value, growth, and momentum categories.

Why it matters — TFX watchers may gain insight into how the stock is being classified and evaluated by Zacks' Style Scores criteria.

5 Low P/B Stocks That Offer Attractive Value and Growth

Zacks Investment Research · 15 Sept 2026positive

Zacks Investment Research identified TFX among five low price-to-book (P/B) stocks, alongside CNC, ENS, ROCK, and FAF, that it says offer attractive value and promising growth prospects. The item highlights TFX as part of this value-and-growth screen.

Why it matters — A TFX watcher would care because the item presents Teleflex favorably within a value-oriented stock screen based on its low P/B valuation and growth outlook.

TFX vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research · 11 Sept 2026neutral

Zacks Investment Research published an article comparing Teleflex (TFX) and Penumbra (PEN) within the Medical - Instruments sector, examining which stock offers better value to investors.

Why it matters — The article evaluates Teleflex's value-investing appeal relative to a peer, providing context for investors considering the stock.

FAQ

Frequently asked questions about TFX stock

What is the TFX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Teleflex, Inc. have a median 12-month price target of $155, with estimates ranging from $138 to $170. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TFX stock a buy right now?

Of the 13 analysts covering Teleflex, Inc., 6 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Teleflex, Inc. 80 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TFX?

As at 3 Oct 2026, Teleflex, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

Will TFX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +23.8% from the last close, and Ticker Nerd's factor model ranks Teleflex, Inc. 80 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TFX stock forecast for 2030?

No analyst covering Teleflex, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TFX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $138 to $170 over the next 12 months.

How has TFX stock performed over the past year?

Teleflex, Inc. returned -3.3% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Teleflex, Inc. do?

Teleflex Incorporated is a global medical technology company that designs, develops, manufactures, and supplies single-use devices used in critical care, surgery, and other hospital procedures. Teleflex Incorporated’s portfolio spans vascular access, anesthesia, emergency medicine, interventional cardiology and radiology, surgical applications, respiratory care, and urology, serving hospitals, healthcare providers, and medical device partners.

What is the latest news on TFX?

The most recent item we track (Business Wire, 29 Sept 2026): "Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology". Teleflex announced the publication of a peer-reviewed study in the American Journal of Infection Control showing that central venous catheters protected with Arrowg+ard Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections compared with plain, non-impregnated catheters over a 30-day period.

Company

About Teleflex, Inc.

Teleflex Incorporated is a global medical technology company that designs, develops, manufactures, and supplies single-use devices used in critical care, surgery, and other hospital procedures. Teleflex Incorporated’s portfolio spans vascular access, anesthesia, emergency medicine, interventional cardiology and radiology, surgical applications, respiratory care, and urology, serving hospitals, healthcare providers, and medical device partners. The company also provides original equipment manufacturing services, supporting other medical device makers with components and specialized products. Its offerings are used in diagnostic and therapeutic procedures that require reliable, procedure-focused tools across a broad range of clinical settings. Headquartered in Wayne, Pennsylvania and founded in 1943, Teleflex Incorporated operates as a diversified healthcare equipment provider with a strong presence across the Americas, EMEA, and Asia.

CEO Mr. Jason Weidman · 15,500 employees · United States · https://www.teleflex.com